PROJECT SUMMARY/ABSTRACT The Immune Monitoring Laboratory Shared Resource (IML) serves as a central hub for basic, translational, and clinical research, uniquely positioned to bridge the wet-bench laboratory and the clinic. The IML mission is to characterize and understand anti-tumor immune responses, determine mechanisms by which immune escape and evasion occur, and predict patient responses and immune related toxicity in cancer immunotherapy trials in support of Perlmutter Cancer Center (PCC) members. To this end, IML centralizes a large portfolio of expert immune monitoring assays, providing easy and affordable access to state-of-the-art services and instrumentation and a collaborative and educational environment for PCC faculty, staff, and students. Directed by Sara Borghi, PhD, an immunologist with extensive expertise in the mechanistic aspects of human immunology and cancer immunotherapy, co-directed by Peter Lopez, PhD, who has has 45 years of experience in flow cytometry, and staffed by 6 other expert scientists, IML has been reorganized to align with PCC member needs for state-of-the art and cutting-edge immune monitoring in support of their project goals and future plans. We collaborate closely with The Applied Bioinformatics Laboratory Shared Resource (ABL), Center for Biospecimen Research and Development Shared Resource (CBRD), Genome Technology Center Shared Resource (GTC), Metabolomics Laboratory Shared Resource (MBX) and Experimental Pathology Shared Resource (ExPath). IML is critical for the research of the four Research Programs, as immune monitoring is central to much of modern cancer research. Most importantly, IML aspires to be flexible in meeting the individual needs of PCC members and in coordinating and integrating different areas of expertise; these needs are assessed regularly via surveys and meetings with an Advisory Board. Since 2018, IML has been used by 106 PCC investigators across all programs, resulting in 168 funded peer-reviewed gran